Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Eggenfelden – page 9

120 clinical trials in Eggenfelden, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Eggenfelden at a glance
120
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

120 trials in Eggenfelden

Open in trial search

Study on Dabigatran and Phenprocoumon for Treating Left Ventricular Thrombosis After Heart Attack in Patients with STEMI

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Medical University Of Graz

Study on the Effectiveness of Enlicitide Chloride in Reducing Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enlicitide decanoate
  • Sponsor:Merck Sharp & Dohme LLC
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GSKVx000000017064
  • Sponsor:GlaxoSmithKline Biologicals

Cardiac failure

Not recruiting

Study on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Hypercholesterolaemia

Not recruiting

Study on Inclisiran and Rosuvastatin for Lowering Cholesterol in Patients with High Cholesterol Levels

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Type 2 diabetes mellitus+2

Not recruiting

Study of LY3502970 for Adults with Obesity or Overweight and Type 2 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.

Neoplasm malignant

Not recruiting

Study on Atezolizumab and Chemotherapy for Patients with Triple-Negative Breast Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:NSABP Foundation Inc.

Study on Ribociclib and Drug Combination for Patients with Advanced HER2-Negative, Hormone Receptor Positive Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Institut Für Frauengesundheit GmbH

Plasma cell myeloma

Not recruiting

Study on Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Low-Risk Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Study of LY3473329 for Adults with High Lipoprotein(a) Levels at Risk for Heart Problems

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Muvalaplin
  • Sponsor:Eli Lilly & Co.

Study on Peppermint Oil and Caraway Oil for Patients with Functional Gastrointestinal Disorders

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Caraway Oil
  • Sponsor:Dr. Willmar Schwabe GmbH & Co. KG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Eggenfelden

What the registry says about research in the country

01 Early-Stage Breast Cancer Research

Groundbreaking clinical trials focusing on hormone receptor-positive (HR+) and HER2-negative early breast cancer treatments, evaluating innovative therapeutic approaches to prevent recurrence.

  • Node-positive breast cancer treatments
  • Extended endocrine therapy evaluation
  • Adjuvant therapy optimization

Studies aim to enhance treatment outcomes through targeted therapeutic combinations.

02 Triple-Negative Breast Cancer Studies

Innovative research exploring the effectiveness of immunotherapy combinations with chemotherapy in treating aggressive forms of breast cancer.

  • Neoadjuvant treatment approaches
  • Chemotherapy optimization
  • Novel drug combinations

Focus on improving survival rates through enhanced treatment protocols.

03 Advanced Breast Cancer Research

Comprehensive studies analyzing treatment patterns and therapeutic resistance in advanced breast cancer, with particular attention to first-line treatment strategies.

  • Molecular pattern analysis
  • Survival rate assessment
  • Treatment resistance mechanisms

Research aims to improve long-term outcomes for patients with advanced disease.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.